Abstract: Provided is an expression vector having an improved ability to express a gene. Also provided are cells transformed by the expression vector and a method for mass-producing a target protein by using the cells. The expression vector contains a simian virus 40 promoter, a scaffold attachment region or matrix attachment region element, and a chimeric intron. The vector shows an improved ability to express a gene, and thus, can attain a significantly increased expression of a heterogeneous gene.
Type:
Grant
Filed:
December 29, 2014
Date of Patent:
May 28, 2019
Assignee:
MOGAM BIOTECHNOLOGY INSTITUTE
Inventors:
Jung-Seob Kim, Seongtae Yun, Heechun Kwak, Mee Sook Oh, Sumin Lee
Abstract: The present invention relates to a novel MDCK-derived cell line capable of being suspension-cultured in a protein-free medium and a method for proliferating a virus using the MDCK-derived cell line to produce a vaccine. The novel MDCK-derived cell line exhibits high and uniform productivity for various viruses, while causing less viral antigenic variations with low tumorigenicity, and thus can be useful in producing viruses used for vaccines.
Type:
Grant
Filed:
June 3, 2014
Date of Patent:
July 10, 2018
Assignee:
MOGAM BIOTECHNOLOGY INSTITUTE
Inventors:
Mihee Hwang, Kukjin Park, Duckhyang Shin, Hyeon Lee, Sooin Kim, Eunyoung Cho, Misuk Kim, Dong Ho Ahn
Abstract: The present invention relates to a method for producing natural killer cells (hereinafter, referred to as “NK cells”), NK cells produced thereby, and a composition for treating cancers and infectious diseases containing the same. The present invention provides a method for producing NK cells, which maintain high cytotoxicity and cell viability to exhibit high therapeutic effects against cancers and infectious diseases and can be cultured ex vivo at high efficiency and high concentration. In addition, a culture method which maintains cell concentration at a constant level is used for the production of NK cells, and thus the overgrowth of the cells can be prevented so that the cells can be maintained at an optimal state. Particularly, even when the cells are thawed after freezing, the function of the cells is not impaired, and the NK cells can maintain high cell viability and cytotoxicity.
Type:
Grant
Filed:
December 18, 2012
Date of Patent:
December 5, 2017
Assignees:
GREEN CROSS LABCELL, MOGAM BIOTECHNOLOGY INSTITUTE
Abstract: The present invention relates to an expression vector having an improved ability to express a gene, cells transformed by the expression vector, and a method for mass-producing a target protein by using the cells. The expression vector according to the present invention shows a more excellent ability to express a gene than a typical animal cell expression vector, and thus, protein expression of a heterogeneous gene can be significantly increased.
Type:
Application
Filed:
December 29, 2014
Publication date:
October 20, 2016
Applicant:
MOGAM BIOTECHNOLOGY INSTITUTE
Inventors:
Jung-Seob KIM, Seongtae YUN, Heechun KWAK, Mee Sook OH, Sumin LEE
Abstract: The present invention relates to a novel MDCK-derived cell line capable of being suspension-cultured in a protein-free medium and a method for proliferating a virus using the MDCK-derived cell line to produce a vaccine. The novel MDCK-derived cell line exhibits high and uniform productivity for various viruses, while causing less viral antigenic variations with low tumorigenicity, and thus can be useful in producing viruses used for vaccines.
Type:
Application
Filed:
June 3, 2014
Publication date:
April 21, 2016
Applicant:
MOGAM BIOTECHNOLOGY INSTITUTE
Inventors:
Mihee HWANG, Kukjin PARK, Duckhyang SHIN, Hyeon LEE, Sooin KIM, Eunyoung CHO, Misuk KIM, Dong Ho AHN
Abstract: The present invention relates to a vaccine composition for preventing staphylococcus aureus infection containing, as an active ingredient, a ribitol-phosphate which has been modified only by a ?-configuration in N-Acetylglucosamine (GlcNAc), a repeating unit of the ribitol-phosphate, or a wall teichoic acid (WTA) containing the repeating unit. The composition according to the present invention contains a coupling motif (an epitope) for an anti-WTA antibody, and thus can be effectively used as a vaccine composition or to prevent staphylococcus aureus infection by generating anti-WTA antibody.
Type:
Application
Filed:
May 7, 2013
Publication date:
May 28, 2015
Applicants:
MOGAM BIOTECHNOLOGY INSTITUTE, PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION
Inventors:
Bok Luel Lee, Kurokawa Kenji, Dong-Jun Jung, Jang-Hyun An, Yu-Jin Jeon, Na Hyang Kim, Takahashi Kazue, Eunmi Kim, Dong Ho Ahn
Abstract: The present invention relates to a method for producing natural killer cells (hereinafter, referred to as “NK cells”), NK cells produced thereby, and a composition for treating cancers and infectious diseases containing the same. The present invention provides a method for producing NK cells, which maintain high cytotoxicity and cell viability to exhibit high therapeutic effects against cancers and infectious diseases and can be cultured ex vivo at high efficiency and high concentration. In addition, a culture method which maintains cell concentration at a constant level is used for the production of NK cells, and thus the overgrowth of the cells can be prevented so that the cells can be maintained at an optimal state. Particularly, even when the cells are thawed after freezing, the function of the cells is not impaired, and the NK cells can maintain high cell viability and cytotoxicity.
Type:
Application
Filed:
December 18, 2012
Publication date:
April 30, 2015
Applicants:
Mogam Biotechnology Institute, Green Cross Labcell